No one — and certainly not NIH — is arguing that
financial ties between academic
investigators and companies, which are pervasive in biomedical research, should be severed.
It notes that
financial conflicts of interest (Duke
investigators had patents on technology and
ties to companies developing the tests) and deference to a senior professor may have influenced the university to dismiss concerns about the papers.